Aetna Receives Neutral Rating from Zacks (AET)
Aetna (NYSE:AET)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued on Friday, StockRatingsNetwork.com reports. They currently have a $71.00 price objective on the stock. Zacks‘ price target would indicate a potential upside of 4.53% from the company’s current price.
Zacks‘ analyst wrote, “Aetna’s fourth-quarter 2013 earnings of $1.34 per share missed the Zacks Consensus Estimate by a penny. Earnings were, however, up 43% year over year. The improvement was driven by earnings accretion from the Coventry acquisition as well as higher underwriting margins primarily in the Commercial business, partially offset by lower underwriting margins in the Medicare business. Earnings in 2014 are expected to be impacted by headwinds related to the Affordable Care Act. However, Aetna is poised to benefit from growth in Medicaid and Medicare segments, fast-growing health services segment and an expanding provider network. Aetna has also made considerable investments in products and technology in a bid to extend its core health business and capitalize on exciting new consumer and provider opportunities emerging in the marketplace. A strong balance sheet with low leverage is another positive. We thus maintain a Neutral recommendation on the stock. “
A number of other analysts have also recently weighed in on AET. Analysts at Leerink Swann upgraded shares of Aetna from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday. Separately, analysts at Credit Suisse upgraded shares of Aetna from a “neutral” rating to an “outperform” rating in a research note to investors on Thursday, January 9th. They now have a $83.00 price target on the stock, up previously from $69.00. Finally, analysts at Barclays raised their price target on shares of Aetna from $75.00 to $80.00 in a research note to investors on Wednesday, January 8th. They now have an “overweight” rating on the stock. Four investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company’s stock. Aetna presently has a consensus rating of “Buy” and an average price target of $74.05.
Aetna (NYSE:AET) traded down 2.00% on Friday, hitting $66.56. The stock had a trading volume of 3,982,157 shares. Aetna has a 52 week low of $46.04 and a 52 week high of $72.16. The stock’s 50-day moving average is $68.87 and its 200-day moving average is $65.66. The company has a market cap of $24.461 billion and a price-to-earnings ratio of 13.73.
Aetna (NYSE:AET) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.34 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.36 by $0.02. The company had revenue of $13.13 billion for the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter last year, the company posted $0.94 earnings per share. Aetna’s revenue was up 46.7% compared to the same quarter last year. Analysts expect that Aetna will post $6.27 EPS for the current fiscal year.
Aetna Inc (NYSE:AET) is a diversified healthcare benefits company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.